Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Harnessing data science to advance radiation oncology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Socioeconomic position and maintenance therapy in children with acute lymphoblastic leukemia: A national cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Inflammatory Response after Moderate Contusion Spinal Cord Injury: A Time Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Minimal residual disease (MRD) constitutes the most important prognostic factor in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Flow cytometry is widely used in MRD assessment, yet little is known regarding the effect of different immunophenotypic subsets on outcome. In this study of 200 BCP-ALL patients, we found that a CD34-positive, CD38 dim-positive, nTdT dim-positive immunophenotype on the leukemic blasts was associated with poor induction therapy response and predicted an MRD level at the end of induction therapy (EOI) of ≥ 0.001. CD34 expression was strongly and positively associated with EOI MRD, whereas CD34-negative patients had a low relapse risk. Further, CD34 expression increased from diagnosis to relapse. CD34 is a stemness-associated cell-surface molecule, possibly involved in cell adhesion/migration or survival. Accordingly, genes associated with stemness were overrepresented among the most upregulated genes in CD34-positive leukemias, and protein-protein interaction networks showed an overrepresentation of genes associated with cell migration, cell adhesion, and negative regulation of apoptosis. The present work is the first to demonstrate a CD34-negative immunophenotype as a good prognostic factor in ALL, whereas high CD34 expression is associated with poor therapy response and an altered gene expression profile reminiscent of migrating cancer stem-like cells.

OriginalsprogEngelsk
TidsskriftMolecular Oncology
Vol/bind16
Udgave nummer10
Sider (fra-til)2015-2030
Antal sider16
ISSN1574-7891
DOI
StatusUdgivet - maj 2022

Bibliografisk note

© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

ID: 78119343